Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 25.71 percent. This is a 69.05 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $81.504 million which beat the analyst consensus estimate of $72.753 million by 12.03 percent. This is a 164.13 percent increase over sales of $30.858 million the same period last year.